0
0

Breakthrough Therapies Act

3/13/2024, 6:54 AM

Congressional Summary of S 5123

Breakthrough Therapies Act

This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. It also provides for expedited controlled substance registrations through the Drug Enforcement Administration for researchers whose work involves investigational drugs.

Current Status of Bill S 5123

Bill S 5123 is currently in the status of Bill Introduced since November 17, 2022. Bill S 5123 was introduced during Congress 117 and was introduced to the Senate on November 17, 2022.  Bill S 5123's most recent activity was Read twice and referred to the Committee on the Judiciary. as of November 17, 2022

Bipartisan Support of Bill S 5123

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 5123

Primary Policy Focus

Crime and Law Enforcement

Alternate Title(s) of Bill S 5123

Breakthrough Therapies Act
Breakthrough Therapies Act
A bill to amend the Controlled Substances Act to modify the registration requirements relating to research, and for other purposes.

Comments